Get the Stockscreener App
4.055
6.99%
+0.265
ProKidney Corp stock is currently priced at $4.055, with a 24-hour trading volume of 544.48K.
It has seen a +6.99% increased in the last 24 hours and a +42.78% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.82 pivot point. If it approaches the $4.12 resistance level, significant changes may occur.
Previous Close:
$3.79
Open:
$3.79
24h Volume:
544.48K
Market Cap:
$259.21M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-7.5738
EPS:
-0.5354
Net Cash Flow:
$-124.27M
1W Performance:
+44.31%
1M Performance:
+42.78%
6M Performance:
+235.12%
1Y Performance:
-60.21%
1D Range:
$3.70
$4.065
52W Range:
$1.12
$13.51
ProKidney Corp Stock (PROK) Company Profile
Name
ProKidney Corp
Sector
Industry
Phone
-
Address
3929 Westpoint Blvd., Suite G, Winston-Salem
ProKidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
ProKidney Corp Stock (PROK) Latest News
Control empresarial de capitales buys $251k in ProKidney shares - Investing.com
Investing.com
ProKidney (NASDAQ:PROK) Shares Down 4.1% - MarketBeat
MarketBeat
This trade activity should not be overlooked: ProKidney Corp (PROK) – Sete News - SETE News
SETE News
Control Empresarial De Capital Buys 14,000 Shares of ProKidney Corp. (NASDAQ:PROK) Stock - MarketBeat
MarketBeat
Investing in ProKidney Corp (PROK) Is Getting More Attractive – Knox Daily - Knox Daily
Knox Daily
ProKidney (NASDAQ:PROK) Shares Gap Down to $4.12 - MarketBeat
MarketBeat
ProKidney Corp Stock (PROK) Financials Data
ProKidney Corp (PROK) Net Income 2024
PROK net income (TTM) was -$35.47 million for the quarter ending December 31, 2023, a +67.17% increase year-over-year.
ProKidney Corp (PROK) Cash Flow 2024
PROK recorded a free cash flow (TTM) of -$124.27 million for the quarter ending December 31, 2023, a -57.43% decrease year-over-year.
ProKidney Corp (PROK) Earnings per Share 2024
PROK earnings per share (TTM) was -$0.57 for the quarter ending December 31, 2023, a +40.09% growth year-over-year.
ProKidney Corp Stock (PROK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weber Darin J. | SVP of Regulatory Development |
Apr 18 '24 |
Sale |
2.54 |
800 |
2,028 |
171,632 |
| Weber Darin J. | SVP of Regulatory Development |
Apr 16 '24 |
Sale |
2.50 |
17,238 |
43,095 |
172,432 |
| Weber Darin J. | SVP of Regulatory Development |
Apr 12 '24 |
Sale |
1.73 |
84,103 |
145,498 |
189,670 |
| Weber Darin J. | SVP of Regulatory Development |
Apr 01 '24 |
Sale |
1.69 |
300 |
507 |
273,773 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Mar 25 '24 |
Buy |
1.43 |
30,000 |
42,954 |
63,295,645 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Mar 22 '24 |
Buy |
1.40 |
14,000 |
19,586 |
63,265,645 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Mar 20 '24 |
Buy |
1.40 |
33,000 |
46,111 |
63,251,645 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Mar 14 '24 |
Buy |
1.36 |
50,000 |
67,925 |
63,218,645 |
| Control Empresarial de Capital | Add'l Rep. Persons-see Ex.99-1 |
Mar 13 '24 |
Buy |
1.50 |
50,000 |
75,090 |
63,168,645 |
| Palihapitiya Chamath | Former 10% Owner |
Nov 19 '23 |
Sale |
1.31 |
7,256,367 |
9,498,584 |
0 |
About ProKidney Corp
ProKidney Corp., a biotech company, operates as a chronic kidney disease therapeutics company. Its lead product candidate, REACT (Renal Autologous Cell Therapy), is a disease modifying cell therapy made from a patient's own renal cells. The company was founded in 2015 and is based in Winston-Salem, North Carolina.
0.77%
1.20%
Cap:
|
Volume (24h):